Paper Details

  1. Home
  2. Paper Details

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.

Author: Audrain-McGovernJ, BenowitzN, BerrettiniW H, KaufmannV, LermanC, PattersonF, ReddenD, RestineS, RukstalisM, ShieldsP G, WileytoE P

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A genetic variant in the mu-opioid receptor (OPRM1) gene was found to predict the efficacy of nicotine replacement therapy (NRT). Smokers with the Asp40 variant had a better response to transdermal nicotine than those with the Asn40 variant.
Paper Details　
Original Abstract of the Article :
To determine whether the functional mu-opioid receptor (OPRM1) Asn40Asp variant predicts the comparative efficacy of different forms of NRT, we conducted a clinical trial of transdermal nicotine (TN) vs nicotine nasal spray (NS) in 320 smokers of European ancestry. Smokers carrying the OPRM1 Asp40 v...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15007373

データ提供：米国国立医学図書館（NLM）

OPRM1 Variant Predicts Nicotine Replacement Therapy Response

Nicotine addiction is a major public health concern, with millions of people struggling to quit smoking. This study investigates the role of the OPRM1 gene, which encodes the mu opioid receptor, in predicting the success of nicotine replacement therapy (NRT). The study examined the association between the OPRM1 Asn40Asp variant and the effectiveness of different forms of NRT, transdermal nicotine (TN) and nicotine nasal spray (NS). The results revealed a significant association between the Asp40 variant and a greater likelihood of abstinence at the end of treatment, particularly for those receiving TN. This research is like a treasure hunt in the desert of addiction research, uncovering genetic clues that may help tailor smoking cessation treatments.

OPRM1 Variant: A Potential Marker for Nicotine Replacement Therapy Success

The study's findings suggest that the OPRM1 Asp40 variant could be a potential predictor of NRT effectiveness, allowing healthcare providers to personalize treatment strategies for smokers seeking to quit. This discovery is like finding a hidden oasis in the desert of addiction research, offering a potential solution for improving the success of smoking cessation treatments.

Personalized Treatment Strategies for Nicotine Addiction

The study emphasizes the importance of considering individual genetic factors when designing smoking cessation interventions. The findings encourage further research into the role of genetics in addiction and the development of more personalized treatment approaches.

Dr.Camel's Conclusion

This study provides valuable insights into the role of the OPRM1 gene in predicting the effectiveness of nicotine replacement therapy. It's like finding a hidden oasis in the vast desert of addiction research, offering a source of hope for those seeking to break free from nicotine dependence. This research encourages continued exploration of genetic factors in addiction, ultimately leading to more effective and personalized treatment strategies.

Date :
  1. Date Completed 2004-12-27
  2. Date Revised 2022-01-14
Further Info :

Pubmed ID

15007373

DOI: Digital Object Identifier

6500238

Related Literature

Article Analysis
・Effects of nicotine nasal spray
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.